Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

ABSTRACT:

Importance

The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive.

Objective

To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC.

Design, setting, and participants

This secondary analysis of a randomized clinical trial used archived DNA samples and cancer family history of 315 patients with TNBC enrolled between August 1, 2011, and December 31, 2012, in the GeparSixto trial. In all, 291 participants (92.4%) were included in

SUBMITTER: Hahnen E 

PROVIDER: S-EPMC5710508 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature